Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,260.56 -46.45 (-0.88%) Dow
39,054.18 -616.86 (-1.55%) Nasdaq
16,694.22 -107.32 (-0.64%) Bitcoin USD
67,274.80 -2,325.79 (-3.34%) CMC Crypto 200
1,459.19 -43.47 (-2.89%)
AMGN Jan 2025 400.000 call
| Previous close | 5.2800 |
| Open | 4.8000 |
| Bid | 4.9500 |
| Ask | 5.4000 |
| Strike | 400.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.8000 - 5.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.34k |
ZacksTop Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
